| Patient | Paul Robeson |
|---|---|
| Date of birth | 1967-04-09 |
| Identifiers | MRN HR-ML048-SYN; SSN (made up) 000-48-2647 |
| Document date | 2026-08-24 |
| Author | Theodore Bankole-Ashworth, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Twenty-four-week review of depression treatment. [S]
Mr. Robeson returns eleven weeks after the switch to venlafaxine; he has taken 225 mg each morning for seven weeks. He sleeps five and a half hours, walks every morning, and has begun to read and see one or two old friends, but he still has little pleasure in music and has not sung in public. The cough from four weeks ago has gone. He sweats a little more than before. He has had no thoughts of suicide since the spring and no elation. He has completed sixteen behavioral activation sessions and continues fortnightly with his psychologist, who reports PHQ-9 scores in the low to mid teens. He asked what else can be done, including whether he would need shock treatment. [S]
| Element | Detail |
|---|---|
| Medicines | Venlafaxine 225 mg for seven weeks, eleven weeks in all |
| Mood | PHQ-9 13 from 22: partial response |
| Side effects | Mild sweating; blood pressure 134/84 |
| Question | What else can be done, including ECT |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Mild sweating; weight 101.0 kg |
| Psychiatric | Positive | Low mood on most days, little pleasure in music; no thoughts of suicide; no elation |
| Respiratory | Negative | Cough gone |
| Cardiovascular | Negative | No palpitations or headache |
| Neurological | Negative | No memory complaint or tremor |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 50 mg tablet, one tablet each morning | 50 mg each morning for two weeks | Oral route | 2026-03-12 to 2026-03-25 | completed | S |
| Sertraline 100 mg tablet, one tablet each morning | 100 mg each morning | Oral route | 2026-03-26 to 2026-04-19 | completed | S |
| Sertraline 50 mg tablets, three tablets (150 mg) each morning | 150 mg each morning for two weeks | Oral route | 2026-04-20 to 2026-05-03 | completed | S |
| Sertraline 100 mg tablets, two tablets (200 mg) each morning | 200 mg each morning | Oral route | 2026-05-04 to 2026-06-07 | completed | S |
| Sertraline 100 mg tablet, one tablet each morning for one week, then stop | 100 mg each morning for one week during the switch | Oral route | 2026-06-08 to 2026-06-14 | completed | S |
| Venlafaxine extended-release 75 mg capsule, one capsule each morning with food | 75 mg each morning for one week | Oral route | 2026-06-08 to 2026-06-14 | completed | S |
| Venlafaxine extended-release 150 mg capsule, one capsule each morning with food | 150 mg each morning for three weeks | Oral route | 2026-06-15 to 2026-07-05 | completed | S |
| Venlafaxine extended-release 75 mg capsules, three capsules (225 mg) each morning with food | 225 mg each morning; 30-day supply at a time | Oral route | 2026-07-06 | active | S |
| Aripiprazole 2 mg tablet, one tablet each morning | 2 mg each morning for two weeks | Oral route | 2026-08-24 to 2026-09-06 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-24 | Body height | 190 | cm | S |
| 2026-08-24 | Body weight | 101 | kg | S |
| 2026-08-24 | Body mass index (BMI) [Ratio] | 28 | kg/m2 | S |
| 2026-08-24 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-08-24 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-08-24 | Heart rate | 78 | /min | S |
| 2026-08-24 | Respiratory rate | 14 | /min | S |
| 2026-08-24 | Body temperature | 36.6 | Cel | S |
| 2026-08-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-24 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-24 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-08-24 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-08-24 | Cholesterol [Mass/volume] in Serum or Plasma | 204 | mg/dL | <=199 mg/dL | High | S |
| 2026-08-24 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-08-24 | Triglyceride [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-08-24 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 132 | mg/dL | <=129 mg/dL | High | S |
| 2026-08-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 13 | {score} | S | ||
| 2026-08-24 | Total score [MoCA] | 28 | {score} | S |
Vital signs recorded on 2026-08-24; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Weight 101.0 kg, BMI 28.0; blood pressure 134/84, pulse 78 |
| Neurological | No tremor, rigidity or abnormal movements; abnormal involuntary movement examination normal |
| Psychiatric | Less slowed; affect a little fuller; logical; no thoughts of suicide |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| About three months of low mood, exhaustion, poor sleep with waking at three in the morning, loss of interest in singing and reading, poor appetite with 5 kg weight loss, and withdrawal from friends, in a man of 58 under sustained political pressure; PHQ-9 22 with thoughts of being better off dead; depression suspected; medical causes being excluded and urgent psychiatric consultation arranged | resolved | confirmed | R53.83 | S — Synthetic presenting problem at intake, superseded by the diagnosis at the psychiatric consultation; anchored to his documented depression and loss of work (D). |
| Major depressive disorder, recurrent, severe, without psychotic features (second episode; structured diagnostic interview; MDQ negative and no past hypomanic or manic episode on interview) | active | confirmed | F33.2 | S — Synthetic modern diagnosis anchored to his documented depression after the 1955 breakdown (D); the bipolar interpretation (R) is addressed and not adopted. |
| Sustained political persecution: passport withheld, concerts and recordings cancelled, income lost, and surveillance by federal agencies; a major and realistic stressor, not a delusion | active | confirmed | Z60.5 | S — Synthetic coding of his documented persecution as a social determinant of his depression. |
| Acute bronchitis after a cold, without signs of pneumonia; treated without antibiotics and without dextromethorphan or decongestants because of venlafaxine; resolved | resolved | confirmed | J20.9 | S — Synthetic intercurrent illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline and at least monthly during acute treatment (CMID) | Completed today | 13, down 41 percent from 22: partial response; item 9 scored 0 |
| Survey | PHQ-9 between visits, rated by the psychologist at each session | At each therapy session | Completed today | Rated at each session; no positive item 9 reported |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, locked medicines and the 988 Suicide & Crisis Lifeline | Every visit during active treatment | Completed today | No thoughts of suicide since the spring; medicines locked; safety plan reviewed |
| Laboratory | Sodium (SSRI or SNRI in an older adult) | Baseline, about four to six weeks after starting, and with symptoms | Completed today | 136 mmol/L, normal |
| Medication safety | Blood pressure (venlafaxine) | Baseline and at every visit on venlafaxine | Completed today | 134/84, up slightly from 128/80; recheck at each visit |
| Medication safety | Adequacy of the antidepressant trial (dose and duration) | At each review: at least four to eight weeks at an adequate dose before judging response | Completed today | Second adequate trial (seven weeks at 225 mg): partial response; treatment-resistant |
| Medication safety | Adherence and adverse-effect review | Every visit | Completed today | Every dose taken; mild sweating |
| Medication safety | Watch for hypomania or mixed features after starting or changing an antidepressant | Every visit; repeat the MDQ if features emerge | Completed today | No signs of hypomania |
| Survey | Cognitive screen (MoCA) | Baseline, and before and during any course of ECT | Completed today | 28, unchanged; kept as a baseline in case ECT is chosen later |
| Medication safety | ECT informed consent discussion and alternatives (rTMS, esketamine) | When depression is treatment-resistant or severe | Completed today | Discussed; ECT not started now by his choice and because there is no urgent indication; available on equal terms if augmentation fails |
| Self-management | Weight and BMI on aripiprazole | Baseline, 4, 8 and 12 weeks, then quarterly (CMID) | Completed today | Baseline 101.0 kg, BMI 28.0 before aripiprazole |
| Laboratory | Hemoglobin A1c or fasting glucose, and lipids, on aripiprazole | Baseline, 12 weeks, then yearly (CMID) | Completed today | A1c 5.6%, glucose 94 mg/dL; total cholesterol 204, HDL 46, triglycerides 130, LDL 132 mg/dL |
| Examination | Abnormal Involuntary Movement Scale | Baseline, then every six months on an antipsychotic (CMID) | Completed today | Baseline examination normal |
| Referral | Behavioral activation with a psychologist | Weekly for sixteen sessions, then fortnightly | Completed today | Sixteen sessions completed; fortnightly sessions continue |
| Referral | Social work for income and costs | Monthly | Completed today | Monthly meetings continue |
Goal progress:
Guideline basis: APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. A Task Force Report of the American Psychiatric Association, 2nd edition (record of the American Journal of Psychiatry review, 2002) (2001); The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. A Task Force Report of the American Psychiatric Association, 3rd edition (Library of Congress catalog record, LCCN 2024014438) (2024); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Williams DR, et al. Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National Survey of American Life. Arch Gen Psychiatry 2007;64(3):305-315 (2007); Sprenger S, et al. Retrospective Cohort Study of Racial-Ethnic Disparities in Receipt of Electroconvulsive Therapy, 2016-2021. Psychiatr Serv 2025;76(8):736-740 (2025)
Follow-up: Nurse phone check in two weeks before the aripiprazole increase. Preventive visit in six weeks with the PHQ-9 and weight. Twelve-week metabolic tests. Call or text 988 at any time in a crisis. Next scheduled visit 2026-10-05: periodic adult preventive visit. [S]